Overall survival (OS) results of phase III ARAMIS study of darolutamide added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

被引：0
|
作者：
Krieger, Laurence [1 ]
Fizazi, Karim [2 ]
Shore, Neal [3 ]
Tammela, Teuvo L. [4 ,5 ]
Ulys, Albertas [6 ]
Vjaters, Egils [7 ]
Polyakov, Sergey [8 ]
Jievaltas, Mindaugas [9 ]
Luz, Murilo [10 ]
Alekseev, Boris [11 ]
Kuss, Iris [12 ]
Le Berre, Marie-Aude [13 ]
Petrenciuc, Oana [14 ]
Snapir, Amir [15 ]
Sarapohja, Toni [15 ]
Smith, Matthew R. [16 ]
机构：
[1] Northern Canc Inst, St Leonards, NSW, Australia
[2] Univ Paris Sud, Inst Gustave Roussy, Paris, France
[3] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[4] Tampere Univ Hosp, Tampere, Finland
[5] Tampere Univ, Tampere, Finland
[6] NCI, Bethesda, MD 20892 USA
[7] Stradins Clin Univ Hosp, Riga, Latvia
[8] NN Alexandrov Natl Canc Ctr Belarus, Liasny, BELARUS
[9] Lithuanian Univ Hlth Sci, Med Acad, Kaunas, Lithuania
[10] Hosp Erasto Gaertner, Curitiba, Parana, Brazil
[11] Minist Hlth Russian Federat, Natl Med Res Radiol Ctr, Moscow, Russia
[12] Bayer AG, Leverkusen, Germany
[13] Bayer Healthcare SAS, Leverkusen, Germany
[14] Bayer Healthcare, Leverkusen, Germany
[15] Orion Corp Orion Pharma, Espoo, Finland
[16] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
abs27
引用
收藏
页码：45 / 46
页数：2
相关论文
共 50 条
  • [21] Apalutamide (APA) and overall survival (OS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Updated results from the phase III SPARTAN study
    Smith, M. R.
    Saad, F.
    Chowdhury, S.
    Oudard, S.
    Hadaschik, B. A.
    Graff, J. N.
    Olmos, D.
    Mainwaring, P. N.
    Lee, J. Y.
    Uemura, H.
    De Porre, P.
    Smith, A.
    Zhang, K.
    Lopez-Gitlitz, A.
    Small, E. J.
    ANNALS OF ONCOLOGY, 2019, 30 : 325 - 325
  • [22] A MODELED HEALTH OUTCOMES EVALUATION OF DAROLUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY FOR HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CHINA
    Ming, J.
    Liu, Y.
    Lu, W.
    Wu, Y.
    Li, W.
    Han, R.
    Hu, S.
    VALUE IN HEALTH, 2021, 24 : S2 - S2
  • [23] Cost–Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China
    Jian Ming
    Yuxia Wu
    Rong Han
    Xing Xu
    Reg Waldeck
    Shanlian Hu
    Advances in Therapy, 2023, 40 : 1087 - 1103
  • [24] Association of prostate specific-antigen doubling time (PSADT) with metastasis-free survival (MFS) and overall survival (OS) in non-metastatic castration-resistant prostate cancer (nmCRPC).
    Lin, Jennifer H.
    Macomson, Brian
    Tunceli, Ozgur
    Pericone, Chris
    Behl, Ajay S.
    Deshmukh, Siddhant
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [25] Artificial intelligence (AI)-based multimodal framework predicts androgen-deprivation therapy (ADT) outcomes in non-metastatic castration resistant prostate cancer (nmCRPC) from SPARTAN
    Mobadersany, Pooya
    Lucas, Justin
    Govind, Darshana
    Aguilar-Bonavides, Clemente
    McCarthy, Sharon
    Brookman-May, Sabine
    Yu, Margaret K.
    Tian, Ken
    Hutnick, Natalie
    Zamalloa, Jose
    Greshock, Joel
    Khan, Najat
    Yip, Stephen S. F.
    CANCER RESEARCH, 2022, 82 (12)
  • [26] Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China
    Ming, Jian
    Wu, Yuxia
    Han, Rong
    Xu, Xing
    Waldeck, Reg
    Hu, Shanlian
    ADVANCES IN THERAPY, 2023, 40 (03) : 1087 - 1103
  • [27] ESTIMATING THE UNBIASED OS-BENEFIT FOR APALUTAMIDE (APA) VERSUS ANDROGEN DEPRIVATION THERAPY (ADT) IN PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) FROM SPARTAN, ADJUSTING FOR SUBSEQUENT THERAPY USING RANDOMIZED DATA EXTERNAL TO THE TRIAL
    Diels, J.
    Perualila, N.
    Sermon, J.
    Siebert, U.
    van Sanden, S.
    VALUE IN HEALTH, 2019, 22 : S103 - S103
  • [28] Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study
    Hegele, Axel
    Haeussermann, Rainer
    Schultheis, Stefan
    Skrobek, Lennart
    Vink, Meike
    Hollwegs, Sebastian
    Ludwig, Martin
    Huwe, Petra
    Maywurm, Manfred
    Bartsch-Polle, Anke
    Weber, Jost
    Thiemer, Markus
    Varughese, Denny
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (09)
  • [29] Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial.
    Smith, Matthew Raymond
    Fizazi, Karim
    Tammela, Teuvo L. J.
    Cruz, Felipe Melo
    Nordquist, Luke T.
    Aleman Polanco, Diana Sofia
    Emmenegger, Urban
    Silveira, Glauco Costa
    Concepcion, Raoul S.
    Paula, Adriano
    de Mendonca Beato, Carlos Augusto
    Fleshner, Neil
    Richardet, Martin Eduardo
    Kuss, Iris
    Le Berre, Marie-Aude
    Borghesi, Gustavo
    Sarapohja, Toni
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [30] Re: Enzalutamide and Survival in Non-metastatic Castration-resistant Prostate Cancer
    Bagguley, Dominic
    Ong, Sean
    Lawrentschuk, Nathan
    Murphy, Declan G.
    EUROPEAN UROLOGY, 2021, 79 (02) : 320 - 321
12345